Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03045341 · ClinicalTrials.gov registry record · Phase 2
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment
A Phase 2 study of Obesity and Binge-Eating Disorder, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 1
- Study location
NCT03045341 is a Phase 2 study of Obesity and Binge-Eating Disorder that has completed, run by Yale University. The registered enrollment target is 136 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03045341, a Phase 2 study of Obesity and Binge-Eating Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the effectiveness and relative efficacy of behavioral and pharmacologic treatments, alone and in combination, for the treatment of binge eating disorder (BED) in patients with obesity. This is an acute treatment comparing behavioral weight loss alone or in combination with naltrexone/bupropion medication.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG NB medication (Naltrexone Bupropion combination)
- BEHAVIORAL Behavioral Weight Loss (BWL) counseling
Study Locations (1)
Connecticut
- Yale School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2022-12-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03045341
The ClinicalTrials.gov registry entry for NCT03045341 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03045341 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03045341 about?
NCT03045341 is a clinical study titled "Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment". This study will test the effectiveness and relative efficacy of behavioral and pharmacologic treatments, alone and in combination, for the treatment of binge eating disorder (BED) in patients with obesity. This is an acute treatment comparing behavioral weight loss alone or in combination with naltr...
What is the current status of trial NCT03045341?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2017-02-27. Estimated completion is 2022-12-16.
What conditions does trial NCT03045341 study?
This clinical trial studies the following conditions: Obesity, Binge-Eating Disorder.
What interventions are being tested in trial NCT03045341?
The interventions under investigation include: Placebo (OTHER), NB medication (Naltrexone Bupropion combination) (DRUG), Behavioral Weight Loss (BWL) counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT03045341?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03045341 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.